Jamminder Singh Bhullar - JPMorgan Securities LLC
Analyst · JPMorgan.
Okay. Thanks. And then on your decision to stop selling life insurance and fixed annuities, your sales haven't been that good to begin with, so I don't think it should have a major impact, but why are you continuing to sell long-term care, and I don't know if that product by selling it, you're better positioned to get rate hikes or not, but maybe just explain your logic on continuing to sell long-term care, but stopping the other product.
Thomas J. McInerney - President, Chief Executive Officer & Director: Yeah. Jimmy, it's Tom. On life and annuity, there are 8,000 life companies selling the product, and if you compare Genworth to the top 20 providers, their ratings were much higher. So while we have monitored the sales in the last few quarters, our conclusion is given that rating differential, we just felt we couldn't be competitive, and we obviously don't have the scale that some of the top 20 players have. And by suspending sales, we save the $50 million of expenses that we talked about. In addition, as you know, because of the significant upfront commissions, particularly on life insurance, that has led to significant statutory strain, so by stopping the sales that also will improve statutory earnings. And under the restructuring where we hope to have GLAIC and GLIC now be sister companies versus GLIC owning GLAIC, we would hope that those higher statutory earnings over time will provide a good dividend stream up to the parent. So that's the story on life and annuity. On LTC, unlike life insurance, there is only a dozen or so LTC players, and really if you look at where the sales are coming from, it's the top five players. And we've – we have always been in the top five, we remain in the top five. So we still do believe competitively we can sell long-term care, and there is no question, if you talk to any of the regulators in any of the states, that our commitment to remain in the business and sell, continue to sell LTC, because of the benefits to the state, Medicaid exposures going forward. They have clearly given Genworth, and I think the other players have remained in more premium increases than those that have discontinued sales.